[go: up one dir, main page]

MX2017003780A - Composicion farmaceutica para tratar colitis ulcerativa. - Google Patents

Composicion farmaceutica para tratar colitis ulcerativa.

Info

Publication number
MX2017003780A
MX2017003780A MX2017003780A MX2017003780A MX2017003780A MX 2017003780 A MX2017003780 A MX 2017003780A MX 2017003780 A MX2017003780 A MX 2017003780A MX 2017003780 A MX2017003780 A MX 2017003780A MX 2017003780 A MX2017003780 A MX 2017003780A
Authority
MX
Mexico
Prior art keywords
ulcerative colitis
pharmaceutical composition
treat ulcerative
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2017003780A
Other languages
English (en)
Other versions
MX381440B (es
Inventor
Sugiura Toshihiko
Kageyama Shunsuke
Goda Yoshiki
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Publication of MX2017003780A publication Critical patent/MX2017003780A/es
Publication of MX381440B publication Critical patent/MX381440B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una composición farmacéutica para tratar colitis ulcerativa, que comprende un compuesto representado por una fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde el compuesto o la sal farmacéuticamente aceptable se administra en una cantidad de 600 mg o más por día a un paciente con colitis ulcerativa.(ver Fórmula).
MX2017003780A 2014-09-29 2015-03-27 Composicion farmaceutica para tratar colitis ulcerativa. MX381440B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014198681 2014-09-29
PCT/JP2015/059717 WO2016051828A1 (ja) 2014-09-29 2015-03-27 潰瘍性大腸炎の治療用医薬組成物

Publications (2)

Publication Number Publication Date
MX2017003780A true MX2017003780A (es) 2017-06-30
MX381440B MX381440B (es) 2025-03-12

Family

ID=55629887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003780A MX381440B (es) 2014-09-29 2015-03-27 Composicion farmaceutica para tratar colitis ulcerativa.

Country Status (9)

Country Link
US (1) US10183022B2 (es)
JP (1) JP6580053B2 (es)
KR (1) KR102319078B1 (es)
AU (1) AU2015326196B2 (es)
BR (1) BR112017006272A2 (es)
CA (1) CA2961311C (es)
EA (1) EA034956B1 (es)
MX (1) MX381440B (es)
WO (1) WO2016051828A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973216T3 (es) * 2018-01-18 2024-06-19 Sterna Biologicals Gmbh Composición para el tratamiento de un paciente que padece colitis ulcerosa y uso de la composición como medicamento
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
KR102758046B1 (ko) 2021-11-05 2025-01-23 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물
CN114668775B (zh) * 2022-02-28 2023-12-19 中国药科大学 纤维素衍生物在制备治疗溃疡性结肠炎药物中的应用
WO2023171789A1 (ja) 2022-03-11 2023-09-14 国立大学法人大阪大学 Ｖｌａ－４の阻害物質を含む、心筋炎を予防、又は治療するための組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2286340C2 (ru) 2000-08-18 2006-10-27 Адзиномото Ко., Инк. Новые производные фенилаланина
EP1595870B1 (en) 2003-02-20 2015-09-23 Ajinomoto Co., Inc. Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
JP4780522B2 (ja) 2003-11-14 2011-09-28 味の素株式会社 フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
WO2005046697A1 (ja) 2003-11-14 2005-05-26 Ajinomoto Co., Inc. フェニルアラニン誘導体の徐放性経口投与製剤
WO2005051525A1 (en) 2003-11-25 2005-06-09 Polyvalor, Limited Partnership Permeation barrier coating or layer with modulated properties and methods of making the same
JP4748449B2 (ja) 2003-11-27 2011-08-17 味の素株式会社 フェニルアラニン誘導体の結晶及びその製造方法
CN102503899B (zh) 2005-06-21 2014-09-24 味之素株式会社 苯基丙氨酸衍生物的结晶、其制备方法及其应用
AU2007322637B2 (en) 2006-11-22 2012-07-05 Ea Pharma Co., Ltd. Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production
US7987289B2 (en) 2008-06-24 2011-07-26 Microsoft Corporation Participating in cloud as totally stubby edge
EP2993173A1 (en) * 2010-03-29 2016-03-09 Ajinomoto Co., Inc. Crystals of salts of phenylalanine derivatives
WO2011122620A1 (ja) 2010-03-29 2011-10-06 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤

Also Published As

Publication number Publication date
BR112017006272A2 (pt) 2018-03-13
AU2015326196A1 (en) 2017-03-23
CA2961311C (en) 2022-12-06
KR20170057435A (ko) 2017-05-24
CA2961311A1 (en) 2016-04-07
JPWO2016051828A1 (ja) 2017-07-27
AU2015326196B2 (en) 2020-05-14
US20170196870A1 (en) 2017-07-13
JP6580053B2 (ja) 2019-09-25
MX381440B (es) 2025-03-12
EA201790726A1 (ru) 2017-11-30
KR102319078B1 (ko) 2021-10-29
US10183022B2 (en) 2019-01-22
EA034956B1 (ru) 2020-04-10
WO2016051828A1 (ja) 2016-04-07

Similar Documents

Publication Publication Date Title
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
CL2019000844A1 (es) Compuesto de piridina.
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
PE20151654A1 (es) Inhibidores de cdc7
PE20150887A1 (es) Compuestos de benceno sustituidos
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
SV2018005682A (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
PH12017500747B1 (en) Heterocyclic compound
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2018006706A (es) Regimenes de dosificacion de melflufen para cancer.
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial